Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 9/20 | 0.37 |
| ▸ | PDE4A | P27815 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442302 | 1.00 | PDE4D (0.37) | PDE4DPDE4AMEN1CHRM1KMT2A | |
| SCHEMBL6442311 | 1.00 | PDE4D (0.37) | PDE4DPDE4AMEN1CHRM1KMT2A | |
| SCHEMBL6441610 | 0.81 | ALDH1A1 (0.39) | PDE4DPDE4AMEN1KMT2APDE4B | |
| SCHEMBL6441615 | 0.81 | ALDH1A1 (0.39) | PDE4DPDE4AMEN1KMT2APDE4B | |
| SCHEMBL6441614 | 0.81 | ALDH1A1 (0.39) | PDE4DPDE4AMEN1KMT2APDE4B | |
| SCHEMBL6442469 | 0.78 | PDE4D (0.42) | PDE4DPDE4AMEN1CHRM1KMT2A | |
| SCHEMBL6442473 | 0.78 | PDE4D (0.42) | PDE4DPDE4AMEN1CHRM1KMT2A | |
| SCHEMBL6442478 | 0.78 | PDE4D (0.42) | PDE4DPDE4AMEN1CHRM1KMT2A | |
| SCHEMBL6442573 | 0.78 | MEN1 (0.37) | PDE4DMEN1CHRM1KMT2AKDM4E | |
| SCHEMBL6442582 | 0.78 | MEN1 (0.37) | PDE4DMEN1CHRM1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303506-B1 | 6-HETEROARYLPHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2005-02-02 | — | — | EP | claimed |
| US-6884802-B2 | 6-heteroarylphenanthridines | ALTANA PHARMA AG (DE) | 2005-04-26 | — | — | US | disclosed |
| EP-1303506-B1 | 6-HETEROARYLPHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040038979-A1 | Treating airway disorders such as asthma. | ALTANA PHARMA AG (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1303506-A1 | 6-HETEROARYLPHENANTHRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002006270-A1 | NOVEL 6-HETEROARYLPHENANTHRIDINES | ALTANA PHARMA AG (DE) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038979-A1 | Treating airway disorders such as asthma. | PTGER4, PDE4B, PDE4A | PDE4D 20/4885PDE4A 3/4885MEN1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.